Immunome, Inc.
IMNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,041 | $14,018 | $0 | $0 |
| % Growth | -35.5% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $9,041 | $14,018 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $129,542 | $23,089 | $23,272 | $14,110 |
| G&A Expenses | $32,955 | $19,657 | $13,629 | $11,094 |
| SG&A Expenses | $32,955 | $19,657 | $13,629 | $11,094 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $152,344 | $80,802 | $0 | $0 |
| Operating Expenses | $314,841 | $123,548 | $36,901 | $25,204 |
| Operating Income | -$305,800 | -$109,530 | -$36,901 | -$25,204 |
| % Margin | -3,382.4% | -781.4% | – | – |
| Other Income/Exp. Net | $12,837 | $2,724 | $5 | $493 |
| Pre-Tax Income | -$292,963 | -$106,806 | -$36,896 | -$24,711 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$292,963 | -$106,806 | -$36,896 | -$24,711 |
| % Margin | -3,240.4% | -761.9% | – | – |
| EPS | -5 | -5.38 | -3.09 | -2.14 |
| % Growth | 7.1% | -74.1% | -44.4% | – |
| EPS Diluted | -5 | -5.38 | -3.09 | -2.14 |
| Weighted Avg Shares Out | 58,639 | 19,844 | 12,127 | 11,539 |
| Weighted Avg Shares Out Dil | 58,639 | 19,844 | 12,127 | 11,539 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,837 | $2,724 | $5 | $10 |
| Interest Expense | $0 | $0 | $5 | $10 |
| Depreciation & Amortization | $2,102 | $728 | $631 | $755 |
| EBITDA | -$151,354 | -$28,000 | -$36,270 | -$24,449 |
| % Margin | -1,674.1% | -199.7% | – | – |